For what indication is a 2 mg intravenous dose of alteplase administered?

Alteplase 2 mg IV: Restoration of Occluded Central Venous Catheter Function

Alteplase 2 mg intravenously is specifically used to restore function to occluded central venous access devices (CVADs), including central venous catheters, peripherally inserted central catheters (PICCs), and implanted ports. This is a distinct indication from the higher doses used for acute ischemic stroke (0.9 mg/kg) or myocardial infarction.

Primary Indication

The 2 mg dose is FDA-approved for treating thrombotic catheter occlusion, defined as the inability to withdraw at least 3 mL of blood from the device or difficulty flushing the catheter 1. This represents a catheter-directed thrombolytic intervention rather than systemic thrombolysis.

Administration Protocol

The drug is instilled directly into the occluded catheter lumen (not given systemically) with the following approach:

• Standard dose: 2 mg in 2 mL for patients ≥30 kg
• Pediatric dose: 110% of internal lumen volume (not exceeding 2 mg/2 mL) for patients <30 kg 1
• Dwell time: 30-120 minutes
• Repeat dosing: If unsuccessful after first dose, a second 2 mg dose may be administered with the same dwell time 1

Clinical Efficacy

The evidence demonstrates robust efficacy across multiple large trials:

• After one dose: 52-75% restoration of catheter function 1, 2, 3
• After two doses: 84-93% cumulative success rate 1, 2, 3
• Pediatric population: 87% overall efficacy in children aged 2-18 years 4
• PICC-specific: 92.9% success rate in 240 patients with occluded PICCs 5

Success rates are higher when occlusion duration is <14 days (88% vs 72% for occlusions >14 days) 6.

Safety Profile

When used for catheter occlusion at the 2 mg dose, alteplase demonstrates excellent safety with minimal systemic exposure:

• Intracranial hemorrhage: 0% across all major trials 1, 2, 3
• Major bleeding: 0.3% (primarily gastrointestinal) 2
• Embolic events: 0% 2
• Sepsis: 0.4% 2

The pharmacokinetics explain this safety profile: when instilled into a catheter rather than given systemically, circulating plasma levels do not reach pharmacologic concentrations. If the 2 mg dose were administered as a systemic bolus, it would return to endogenous levels (5-10 ng/mL) within 30 minutes 1.

Critical Distinctions from Stroke Dosing

Do not confuse this indication with acute ischemic stroke treatment:

• Stroke dose: 0.9 mg/kg (maximum 90 mg) given systemically over 60 minutes 7
• Catheter dose: 2 mg instilled locally into the catheter lumen 1
• Route: Catheter instillation vs. intravenous infusion
• Risk profile: Minimal systemic exposure with catheter use vs. significant bleeding risk with stroke dosing

Practical Considerations

Before administering alteplase for catheter occlusion:

1. Confirm thrombotic occlusion - exclude mechanical causes (catheter malposition, kinking, suture constriction, lipid deposits) 1
2. Avoid vigorous suction - can damage vessel wall or collapse soft-walled catheters 1
3. Use gentle instillation - excessive pressure may rupture catheter or expel clot into circulation 1
4. Exercise caution with infected catheters - may release localized infection into systemic circulation 1

Relative contraindications for catheter use include:

• Active internal bleeding
• Recent surgery, delivery, or biopsy within 48 hours
• Thrombocytopenia or coagulopathy
• Severe hepatic or renal disease 1

Catheter Types Treated

Efficacy is consistent across all catheter types 1:

• Single-lumen catheters
• Double-lumen catheters
• Triple-lumen catheters
• Implanted ports
• PICCs
• Apheresis catheters

The 30-day catheter patency rate following successful treatment is approximately 74%, with 26% experiencing recurrent dysfunction 1.